immunotherapeutics love



from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. Plural form of immunotherapeutic.


Sorry, no etymologies found.


  • NYSE Amex: INO, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has expanded its scientific advisory board with the appointment of two prominent leaders in the fields of vaccines and cancer immunotherapeutics.

  • ONCS.ob - News develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics.

  • Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor.


  • Moffitt Cancer Center has a 206 bed cancer hospital dedicated to clinical research, including vaccine and immunotherapy of cancer, and has state-of-the-art core facilities for cell therapy and immunotherapeutics, flow cytometry, proteomics, gene profiling, transgenic mouse models, and in vivo animal imaging.

    Naturejobs - All Jobs

  • The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.


  • Two tumor immunotherapeutics are currently in Phase lla clinical development.

    Naturejobs - All Jobs

  • About Advaxis, Inc. Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer.

    The Earth Times Online Newspaper

  • 'S-Hertogenbosch, The Netherlands, April 27, 2010 - Immunovo BV, a new biotechnology company developing a novel technology platform for the creation of a new generation of immunotherapeutics, has secured seed funding from Biox Biosciences BV and LUPUS Ventures BV. Featured News and Stories

  • "We are delighted about the prospect of creating a novel class of highly specific immunotherapeutics with a world class technology platform, and a very promising and well-filled product pipeline", said Cees de Wolff from Lupus Ventures. Featured News and Stories

  • Evaluating potential of Ampligen and TLR3 agonists as cancer immunotherapeutics



Log in or sign up to get involved in the conversation. It's quick and easy.